New hope for myasthenia crisis: early ravulizumab may speed ICU recovery

NCT ID NCT07411963

Recruiting now Disease control Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether giving the drug ravulizumab early, right after standard crisis treatments like plasma exchange or IVIg, can help people with severe myasthenia gravis recover faster in the ICU. About 30 adults with a specific antibody type will be followed for 6 months. The goal is to see if this approach shortens time on a ventilator, reduces hospital stay, and improves muscle strength.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ravulizumab (Ultomiris)
What this could lead to: If early ravulizumab helps patients recover faster from a myasthenic crisis, it could shorten ICU stays and reduce complications, improving care for this rare condition.
What could go wrong: This is a small observational study (30 patients) with no control group, so results may not prove cause and effect. Ravulizumab is already approved for maintenance, but its early use in crisis is not yet validated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myasthenia gravis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYASTHENIA GRAVIS

Contacts and locations

Locations

CHU de NICE
RECRUITING

Nice, Alpes-maritimes, 06000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.